Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons.
暂无分享,去创建一个
[1] H. Bartsch,et al. Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers. , 1999, Cancer detection and prevention.
[2] K. Dold,et al. Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1 beta. , 1991, Science.
[3] D. Nebert,et al. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. , 1982, Pharmacological reviews.
[4] C. Guillemette,et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.
[5] J. Williams. Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. , 2001, Carcinogenesis.
[6] D. Nebert,et al. Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. , 1985, Nucleic acids research.
[7] H. Yamazaki,et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.
[8] A. Luch,et al. Comparison of cytochrome P450- and peroxidase-dependent metabolic activation of the potent carcinogen dibenzo[a,l]pyrene in human cell lines: formation of stable DNA adducts and absence of a detectable increase in apurinic sites. , 1999, Cancer research.
[9] D. Jerina,et al. Tumorigenicity studies with diol-epoxides of benzo(a)pyrene which indicate that (+/-)-trans-7beta,8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene is an ultimate carcinogen in newborn mice. , 1978, Cancer research.
[10] K. Keyomarsi,et al. Expression of cytochromes P450 in human breast tissue and tumors. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[11] A. Jaiswal,et al. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[12] Y Fujii-Kuriyama,et al. Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. , 2005, Biochemical and biophysical research communications.
[13] H. Gelboin,et al. Aryl hydrocarbon hydroxylase and polycyclic hydrocarbon tumorigenesis: effect of the enzyme inhibitor 7,8-benzoflavone on tumorigenesis and macromolecule binding. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[14] Jennifer L. Martin,et al. Human sulfotransferases and their role in chemical metabolism. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[15] S. Anttila,et al. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[16] B. Hammock,et al. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. , 2005, Annual review of pharmacology and toxicology.
[17] Allan B. Okey,et al. Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer* , 2004, Journal of Biological Chemistry.
[18] P. Farmer,et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.
[19] T. Sutter,et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. , 1998, Carcinogenesis.
[20] T. Brüning,et al. Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma. , 1999, Pharmacogenetics.
[21] T. Shimada,et al. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1 , 2004, Cancer science.
[22] A. Rettie,et al. Functional analysis of human microsomal epoxide hydrolase genetic variants. , 2004, Chemico-biological interactions.
[23] H. Swanson,et al. Cloning and expression of a human Ah receptor cDNA. , 1993, Molecular pharmacology.
[24] N. Ozawa,et al. A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[alpha]anthracene. , 1982, Science.
[25] J. Yokota,et al. Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese Population , 1999, Japanese journal of cancer research : Gann.
[26] M. Spitz,et al. An association between a NQO1 genetic polymorphism and risk of lung cancer. , 2005, Mutation research.
[27] O. Gotoh,et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. , 2000, Pharmacogenetics.
[28] A. Conney,et al. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. , 1982, Cancer research.
[29] A. Brøgger,et al. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. , 1991, Pharmacogenetics.
[30] C. Ioannides. METABOLIC-ACTIVATION OF POLYCYCLIC AROMATIC-HYDROCARBONS , 1988 .
[31] A. Daly,et al. Pharmacogenetics of the major polymorphic metabolizing enzymes , 2003, Fundamental & clinical pharmacology.
[32] H. Kleiner,et al. Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. , 2002, Chemical research in toxicology.
[33] P. Harper,et al. Polymorphisms in the human AH receptor. , 2002, Chemico-biological interactions.
[34] N. Roodi,et al. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.
[35] Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. , 1998 .
[36] S. Amin,et al. Tumorigenicity in newborn mice of fjord region and other sterically hindered diol epoxides of benzo[g]chrysene, dibenzo[a,l]pyrene (dibenzo[def,p]chrysene), 4H-cyclopenta[def]chrysene and fluoranthene. , 1995, Carcinogenesis.
[37] S. London,et al. Correspondence re: S. J. London et al., Lung Cancer Risk in African-Americans in Relation to a Race-specific CYP1A1 Polymorphism. Cancer Res., 55: 6035–6037, 1995. — Reply , 1996 .
[38] T. Slaga,et al. The effects of benzoflavones on polycyclic hydrocarbon metabolism and skin tumor initiation. , 1977, Chemico-biological interactions.
[39] J. Schenkman,et al. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. , 2005, Archives of biochemistry and biophysics.
[40] T. Slaga,et al. Inhibition of the binding of 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene to DNA in mouse skin epidermis by 1-ethynylpyrene. , 1990, Carcinogenesis.
[41] A. Olshan,et al. Selected Genetic Polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and Risk of Head and Neck Cancer: A Pooled Analysis , 2005, Cancer Epidemiology Biomarkers & Prevention.
[42] D. Nebert,et al. Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate , 2006, Molecular Pharmacology.
[43] R. Weinshilboum,et al. Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. , 1999, Biochemical pharmacology.
[44] R. Hayes,et al. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[45] J. Freudenheim,et al. Microsomal epoxide hydrolase variants are not associated with risk of breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[46] S. London,et al. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. , 1995, Cancer research.
[47] H. Bartsch,et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[48] T. Shimada,et al. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.
[49] D. Jerina,et al. (+/-)-trans-7,8-dihydroxy-7,8-dihydrobenzo (a)pyrene: a potent skin carcinogen when applied topically to mice. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[50] H. Yamazaki,et al. Inhibition of human cytochrome P450-catalyzed oxidations of xenobiotics and procarcinogens by synthetic organoselenium compounds. , 1997, Cancer research.
[51] M. Manns,et al. Polymorphisms of the Carcinogen Detoxifying UDP-Glucuronosyltransferase UGT1A7 in Proximal Digestive Tract Cancer , 2002, Zeitschrift fur Gastroenterologie.
[52] L. Marnett,et al. Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. , 1989, Cancer research.
[53] J. Little,et al. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. , 2005, American journal of epidemiology.
[54] A. Tjønneland,et al. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. , 2005, Cancer letters.
[55] S. Lewis,et al. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. , 2001, Lung cancer.
[56] C. Eap,et al. Identification of a novel splice-site mutation in the CYP1A2 gene. , 2003, British journal of clinical pharmacology.
[57] M. Spiteri,et al. Glutathione-S-transferase family of enzymes. , 2001, Mutation research.
[58] H. Yamazaki,et al. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[59] T. Shimada,et al. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[60] R. Weinshilboum,et al. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. , 1997, Biochemical and biophysical research communications.
[61] T. Shimada,et al. Recombinant Enzymes Overexpressed in Bacteria Show Broad Catalytic Specificity of Human Cytochrome P450 2W1 and Limited Activity of Human Cytochrome P450 2S1 , 2006, Molecular Pharmacology.
[62] M. Tockman,et al. Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk , 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[63] X. Shu,et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[64] C. Kiyohara. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. , 2000, Journal of epidemiology.
[65] L. Wienkers,et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.
[66] J. Ioannidis,et al. Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[67] P. Beaune,et al. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. , 1992, Molecular pharmacology.
[68] C. Miller,et al. Quantitative analysis of constitutive and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[69] T. Shirakawa,et al. Genetic polymorphisms and lung cancer susceptibility: a review. , 2002, Lung cancer.
[70] F. Guengerich,et al. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. , 1985, The Journal of biological chemistry.
[71] A. Luch,et al. Metabolic activation of dibenzo[a,l]pyrene by human cytochrome P450 1A1 and P450 1B1 expressed in V79 Chinese hamster cells. , 1999, Chemical Research in Toxicology.
[72] C. Griffin,et al. Isolation and Characterization of the Human Cytochrome P450 CYP1B1 Gene* , 1996, The Journal of Biological Chemistry.
[73] I. Roots,et al. High frequency of CYP1A1 mutations in a Turkish population , 1998, Archives of Toxicology.
[74] H. Kleiner,et al. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. , 2003, Chemical research in toxicology.
[75] D. Nebert,et al. Genetic mechanisms controlling the induction of polysubstrate monooxygenase (P-450) activities. , 1981, Annual review of pharmacology and toxicology.
[76] J. Brockmöller,et al. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. , 1996, Cancer research.
[77] W. Trager,et al. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.
[78] Y Fujii-Kuriyama,et al. Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. , 1994, The Journal of biological chemistry.
[79] C. Jefcoate,et al. A novel adrenocorticotropin-inducible cytochrome P450 from rat adrenal microsomes catalyzes polycyclic aromatic hydrocarbon metabolism. , 1991, Endocrinology.
[80] F. Guengerich,et al. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. , 1999, Biochemical and biophysical research communications.
[81] D. Nebert,et al. Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse , 1975, Journal of cellular physiology.
[82] K. Nakachi,et al. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. , 1991, Journal of biochemistry.
[83] P. Workman,et al. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. , 2000, Molecular pharmacology.
[84] T. Shirakawa,et al. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer , 2002, Environmental health and preventive medicine.
[85] E. Schuetz,et al. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. , 1992, Archives of biochemistry and biophysics.
[86] Xinxin Ding,et al. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.
[87] E. Taioli,et al. A novel CYP1A1 gene polymorphism in African-Americans. , 1993, Carcinogenesis.
[88] Xifeng Wu,et al. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. , 2003, Cancer letters.
[89] D. Warshawsky,et al. Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review. , 2005, Toxicology and applied pharmacology.
[90] Y. Fujii‐Kuriyama,et al. Functional role of AhR in the expression of toxic effects by TCDD. , 2003, Biochimica et biophysica acta.
[91] E. Jabs,et al. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. , 1994, The Journal of biological chemistry.
[92] Norman R. Farnsworth,et al. Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.
[93] J. Ward,et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[94] Y. Fujii‐Kuriyama,et al. P450 and Human Cancer , 1991, Japanese journal of cancer research : Gann.
[95] T. Shimada,et al. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. , 1992, Cancer research.
[96] S. Hecht,et al. Tobacco smoke carcinogens and breast cancer , 2002, Environmental and molecular mutagenesis.
[97] L. Marchand,et al. Association of the NAD(P)H:quinone oxidoreductase 609C-->T polymorphism with a decreased lung cancer risk. , 1999, Cancer research.
[98] C. Jefcoate,et al. Ah receptor regulation of mouse Cyp1B1 is additionally modulated by a second novel complex that forms at two AhR response elements. , 2003, Toxicology and applied pharmacology.
[99] D. Roop,et al. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. , 2000, Cancer research.
[100] C. Tohyama,et al. Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[101] G. Shenfield,et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.
[102] T. Shimada,et al. Metabolic activation of environmental carcinogens and mutagens by human liver microsomes. Role of cytochrome P-450 homologous to a 3-methylcholanthrene-inducible isozyme in rat liver. , 1988, Biochemical pharmacology.
[103] P. Watkins,et al. THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.
[104] F. Gonzalez,et al. Targeted Disruption of the Microsomal Epoxide Hydrolase Gene , 1999, The Journal of Biological Chemistry.
[105] T. Shimada,et al. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. , 1991, Chemical research in toxicology.
[106] P. Harper,et al. The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. , 1994, Toxicology letters.
[107] T. Shimada,et al. Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[108] T. Shimada,et al. Specificity of 17β-oestradiol and benzo[α]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432 , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[109] T. Kamataki,et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.
[110] H. Mohrenweiser,et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.
[111] A. Spurdle,et al. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. , 2001, Carcinogenesis.
[112] K. Nagata,et al. Genetic polymorphism of human cytochrome p450 involved in drug metabolism. , 2002, Drug metabolism and pharmacokinetics.
[113] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[114] E. LaVoie,et al. Tumour initiating activity of dihydrodiols of benzo[b]fluoranthene, benzo[j]fluoranthene, and benzo[k]fluoranthene. , 1982, Carcinogenesis.
[115] Teruhiko Yoshida,et al. Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients , 2003, Journal of Pharmacology and Experimental Therapeutics.
[116] M. Ingelman-Sundberg,et al. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. , 1997, Biochemical and biophysical research communications.
[117] M. Spitz,et al. Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. , 2002, Lung cancer.
[118] K. Humphreys,et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. , 2003, Carcinogenesis.
[119] Slobodan Petar Rendic. Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.
[120] E. Cavalieri,et al. Identification and quantification of the depurinating DNA adducts formed in mouse skin treated with dibenzo[a,l]pyrene (DB[a,l]P) or its metabolites and in rat mammary gland treated with DB[a,l]P. , 2005, Chemical research in toxicology.
[121] T. Shimada,et al. Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. , 1999, Chemical research in toxicology.
[122] N. Palackal,et al. The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: potential role in polycyclic aromatic hydrocarbon activation. , 2001, Biochemistry.
[123] K. Nakachi,et al. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. , 1993, Cancer research.
[124] A. Luch,et al. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. , 2002, Chemical research in toxicology.
[125] J. Liehr,et al. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[126] J. Ferguson,et al. Effect of a complex environmental mixture from coal tar containing polycyclic aromatic hydrocarbons (PAH) on the tumor initiation, PAH-DNA binding and metabolic activation of carcinogenic PAH in mouse epidermis. , 2001, Carcinogenesis.
[127] E. Glover,et al. Chlorinated biphenyl induction of aryl hydrocarbon hydroxylase activity: a study of the structure-activity relationship. , 1977, Molecular pharmacology.
[128] T. Rebbeck,et al. Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[129] M. Ingelman-Sundberg,et al. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. , 1999, Drug metabolism reviews.
[130] N. Hamajima,et al. Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. , 2005, Gynecologic oncology.
[131] E. Glover,et al. Analysis of the four alleles of the murine aryl hydrocarbon receptor. , 1994, Molecular pharmacology.
[132] T. Shimada,et al. Dose-response studies on the induction of liver cytochromes P4501A1 and 1B1 by polycyclic aromatic hydrocarbons in arylhydrocarbon-responsive C57BL/6J mice , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[133] M. Sarfarazi,et al. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. , 1997, Human molecular genetics.
[134] Kazuo Komamura,et al. Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes , 2004, Journal of Pharmacology and Experimental Therapeutics.
[135] D. Roop,et al. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. , 2001, Journal of the National Cancer Institute.
[136] G. Coetzee,et al. CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[137] T. Penning,et al. Aldo-keto reductases and formation of polycyclic aromatic hydrocarbon o-quinones. , 2004, Methods in enzymology.
[138] M. Ingelman-Sundberg,et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. , 2003, Molecular pharmacology.
[139] Á. Rodríguez-Lescure,et al. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. , 2002, Cancer letters.
[140] H. Gelboin,et al. Dimethylbenzanthracene Tumorigenesis and Aryl Hydrocarbon Hydroxylase in Mouse Skin: Inhibition by 7,8-Benzoflavone , 1970, Science.
[141] T. Shimada,et al. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. , 2002, Carcinogenesis.
[142] D. Nebert,et al. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.
[143] Jingweng Wang,et al. GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population. , 2003, Cancer letters.
[144] D. Albanes,et al. Polymorphisms in glutathione-S-transferase genes (GST-M1, GST-T1 and GST-P1) and susceptibility to prostate cancer among male smokers of the ATBC cancer prevention study , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[145] R. Millikan,et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. , 2000, Cancer research.
[146] D. Nebert,et al. Human P(3)450: cDNA and complete protein sequence, repetitive Alu sequences in the 3' nontranslated region, and localization of gene to chromosome 15. , 1987, Journal of experimental pathology.
[147] H. Ganther,et al. Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. , 1994, Carcinogenesis.
[148] Paolo Boffetta,et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review , 2002, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[149] T. Penning,et al. The aldo-keto reductase superfamily homepage. , 2003, Chemico-biological interactions.
[150] J. Yokota,et al. Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[151] F. Guengerich,et al. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. , 2001, Cancer research.
[152] Y. Fujii‐Kuriyama,et al. Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. , 1995, Pharmacogenetics.
[153] R. Kim,et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.
[154] W. Levin,et al. Purification and characterization of hepatic microsomal cytochrome P-450. , 1990, Pharmacology & therapeutics.
[155] A. Child,et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. , 1998, American journal of human genetics.
[156] T. Shimada,et al. Tissue-specific induction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene. , 2003, Toxicology and applied pharmacology.
[157] H. Echizen,et al. Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients , 2003, Clinical pharmacology and therapeutics.
[158] C. Jefcoate,et al. Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. , 1990, Carcinogenesis.
[159] G. Clark,et al. Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals. , 1995, Carcinogenesis.
[160] Y. Fujii‐Kuriyama,et al. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. , 1999, Genes & development.
[161] H. Mukhtar,et al. Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. , 1998, Biochemical pharmacology.
[162] Trevor M Penning,et al. Competing roles of cytochrome P450 1A1/1B1 and aldo-keto reductase 1A1 in the metabolic activation of (+/-)-7,8-dihydroxy-7,8-dihydro-benzo[a]pyrene in human bronchoalveolar cell extracts. , 2005, Chemical research in toxicology.
[163] D. Ross,et al. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. , 2004, Methods in enzymology.
[164] K Chiba,et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.
[165] F. Guengerich,et al. Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. , 1996, Cancer research.
[166] W. F. Greenlee,et al. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. , 2001, Annual review of pharmacology and toxicology.
[167] W. Baer-Dubowska,et al. Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. , 1997, Carcinogenesis.
[168] J. Chang-Claude,et al. SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case–control study , 2005, Breast Cancer Research.
[169] J A McKay,et al. Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.
[170] T. Shimada,et al. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. , 2006, Chemical research in toxicology.
[171] E. Taioli,et al. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. , 1995, Cancer research.
[172] S. Anttila,et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. , 1997, Carcinogenesis.
[173] H. Yamazaki,et al. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. , 1998, Chemical research in toxicology.
[174] Y. Chun,et al. Discovery of cytochrome P450 1B1 inhibitors as new promising anti‐cancer agents , 2003, Medicinal research reviews.
[175] T. Slaga,et al. Potent inhibitory effects of suicide inhibitors of P450 isozymes on 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene initiated skin tumors. , 1991, Carcinogenesis.
[176] K Trieb,et al. Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk , 2003, British Journal of Cancer.